Skip to main content

Table 3 Change of secondary outcomes in participants

From: Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus

Term Type Baseline 12 weeks 24 weeks
FBG (mg/dL) 1 160.8 ± 68.7 150.2 ± 37.4 149.4 ± 46.7
2 152.9 ± 61.5 141.1 ± 50.0 142.1 ± 51.5
1.5-AG (μg/mL) 1 6.9 ± 5.5 7.8 ± 6.5 9.7 ± 8.8
2 8.0 ± 4.9 10.4 ± 7.2 10.4 ± 5.5
Bolus insulin (IU/day) 1 20.3 ± 6.5 19.4 ± 7.1 19.0 ± 7.3
2 19.9 ± 5.7 20.1 ± 5.5 20.0 ± 5.6
Basal insulin (IU/day) 1 14.4 ± 5.1 12.3 ± 5.0 * 12.3 ± 6.1 *
2 13.4 ± 7.6 11.9 ± 6.7 * 11.4 ± 6.3 *
Body weight (kg) 1 58.7 ± 11.4 57.9 ± 10.8 57.5 ± 11.1
2 66.6 ± 14.7 66.8 ± 14.7 66.9 ± 14.6
  1. Data are mean ± SD. Comparisons were made by ANOVA. * p < 0.05, significantly different from baseline